医薬品の開発に
「実りある」
患者・市民参画を育てる
Multi-stakeholder Co-creation
Social co-creation with patients and public
Inclusive and sustainable participation from diverse backgrounds
Equitable and reciprocal benefits
Ongoing opportunities for mutual learning – not just receiving support or making requests
Concrete actions
Robust planning to return value to society
Clinical Trial Ambassador Project
Empirical research 'Using PED as Evidence'
A pilot case study 'Building PED using metaverse'
Patient-focused clinical trial ecosystem
Supporting citizen science
Interdisciplinary Approach to Science
Empirical research activities that foster patient and public involvement (PPI)
A Focus on Societal Implementation
Consultation to implement PPI
We offer consultations on PPI
in medicines development and clinical research.
Our team—representing various professional backgrounds—works with
companies, researchers, healthcare providers, and patient groups
to help put PPI into practice.
Participation in PFMD's initiative
Patient engagement and patient experience data
Patient engagement in health technology assessment
Global clinical trials ecosystem
Co-hosted by 1st PEOF+ Asia Pacific in Manila in 2026.
A Global Perspective
Systematizing PPI through international collaboration
Events & Projects
Our Milestones
2020 In Austria, Boehringer Ingelheim and European Patients' Academy on Therapeutic Innovation (EUPATI) jointly launched the Clinical Trial Ambassador Project. The first training sessioin for patient organizations was delivered.
2021 Bringing Patient Education to Japan - Boehringer Ingelheim, patient organizations, and researchers comes together to design a Japanese version of the Clinical Trial Ambassador Project.
2022 Collaboration beyond Organizational Boundaries - Volunteers from pharmaceutical companies, patient organizations, and academia worked togather to deliver the first Clinical Trial Ambassador Training program in Japan. Six patient representatives completed the training and became Clinical Trial Ambassadors.
2024 Expanding Innovation for Society - To strengthen the public value, transparency, and credibility of the Clinical Trial Ambassador Project, its governing body was establised as a non-profit organization. On April 25, YORIAILab was officially founded as a general incorporated association.
2025 Building a Co-creation Community - To further advance patient and public involvement (PPI) in healthcare and medicines development, YORIAILab expanded its activities beyond the Clinical Trial Ambassador Project, strengthening education, partnerships, and research. By this year, 52 patients and members of the public had completed the Clinical Trial Ambassador Training program and becoming contributors to a growing co-creation community.
Highlights
Latest information on events and resources ➡️
Clinical Trial Ecosystem
To advance a healthcare ecosystem shaped by patient perspectives, we contribute to discussions on the implementation of Decentralized Clinical Trials (DCTs). In February and March 2026, we organized workshops with Clinical Trial Ambassadors to explore the future of DCTs from the patient perspective. We also collaborate with healthcare institutions to support the implementation of patient and public involvement (PPI) in clinical research.
News
Latest information on events and resources ➡️
June 27, 2026 New
YORIAILab supported the 3rd Joint Study Meeting for Skin Disease Patient Organizations (1–5 pm), co-hosted by Maruho Co., Ltd. at TKP Garden City Tokyo Station Marunouchi Central. Our representative gave a presentation titled "Creating Healthcare Value through Patients' Experiences: Patient Engagement and Patient Experience Data." During the workshop, participants shared practical ideas on how patient organizations could use patients' experiences as data to address everyday challenges. The event provided a valuable opportunity to deepen participants' understanding of patient experience data and its role in creating value for patients and healthcare.
June 22, 2026 New
We held our 2026 Annual General Meeting on Tuesday, June 23. During the meeting, we presented a review of our activities over the past year, and members approved our business plan for the coming year as well as the new Board of Directors➡️. Following the meeting, we hosted the third YORIAI roundtable for Clinical Trial Ambassadors. Participants, including people living with rare diseases and other chronic conditions, exchanged perspectives on the current state of clinical trials and their hopes and expectations for the future.
June 22, 2026 New
We have added a Japanese version of a searchable training resource on Patient Experience Data (PED)➡️ . Developed by Boehringer Ingelheim in Germany, this tool was generously provided to YORIAILab at no cost so that it can be widely used by the community.
June12, 2026
We held the third workshop on providing information about clinical trials with our clinical trial ambassadors. Various questions and opinions were raised during the three workshops regarding the notification issued by the Ministry of Health, Labour and Welfare, "Handling of Information Provision Related to Clinical Trials, etc." (March 30, 2026, Pharmaceutical and Medical Affairs Bureau Notification No. 0330-1), and its accompanying Q&A document. A summary of the workshops will be published on our website soon. Please note that the Japan Pharmaceutical Manufacturers Association has also provided an explanation of this notification.
June 9, 2026
YORIAILab is pleased to co-host this year's DIA Bioethics Community Seminar. The seminar, titled "How Can Patient Experience Transform Clinical Trials? Exploring the Future of Clinical Research through ICH E22," will be held on the evening of August 25. Registration opens today. For further details and registration information, please visit ➡️.
June 8, 2026
From June 2–4, YORIAILab participated in Patient Engagement Open Forum (PEOF) 2026 in Seville, Spain. This year's theme: Strengthening Common Ground. Building Practical Solutions. Widening the Circle. We engaged in constructive discussions on topics including Patient Experience Data (PED), as well as how patient engagement activities and their impact can be evaluated. The event also provided valuable opportunities to connect with patient engagement leaders and experts from around the world.
June 8, 2026
As part of preparations for PEOF+ Asia Pacific (November 17–19, Manila, Philippines), YORIAILab formally signed a licensing agreement on May 27 with The Synergists, the Brussels-based organization behind PFMD. At PEOF 2026, YORIAILab was also introduced as one of the organizations leading the development of regional PEOF+ events around the world.
Public consultation
Public comment collection on new systems and guidelines regarding patient and public involvement
There are currently no open public consultations.
If you have any questions, please contact us here: ✉ nobutaka.yagi@yoriailab.com
